New drug combo aims to boost surgery success in colon cancer

NCT ID NCT07677579

Not yet recruiting Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receive the drug combination for six weeks, then undergo surgery within 14 to 35 days. The main goal is to see how many patients can proceed to surgery as planned, while also checking for side effects and signs that the tumor has shrunk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zanzalintinib and Retifanlimab
What this could lead to: If successful, this approach could make surgery more effective and reduce the chance of cancer returning in patients with early-stage colon cancer.
What could go wrong: This is a small, early-phase trial, so results may not apply to all patients. The combination therapy may cause side effects or fail to improve outcomes compared to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma metastatic malignant neoplasm metastatic malignant neoplasm in the colon

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER METASTATIC

More trials for these conditions

Other studies related to the condition(s) this trial covers.